Mesoblast Ltd. (MSB) and Lonza reported that they have entered into an agreement for commercial manufacture of Mesoblast’s lead allogeneic (off-the-shelf) cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease (aGVHD)
http://crweworld.com/article/news-provided-by-globenewswire/1276938/mesoblast-and-lonza-enter-into-agreement-for-commercial-manufacture-of-mesoblasts-potential-first-united-states-allogeneic-cell-therapy
Mesoblast Ltd. (MSB) and Lonza reported that they have entered...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.025(2.38%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.06 | $1.06 | $1.02 | $5.734M | 5.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 203347 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 125348 | 6 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
-0.025 ( 2.94 %) |
||||
| Open | High | Low | Volume | ||
| $1.06 | $1.06 | $1.02 | 953870 | ||
| Last updated 15.59pm 16/05/2024 ? | |||||
| MSB (ASX) Chart |